Ondansetron

This publication has 35 references indexed in Scilit:

• Double-blind crossover trial of single vs. divided dose of metoclopramide in a combined regimen for treatment of cisplatin-induced emesis
  European Journal of Cancer and Clinical Oncology, 1991
• Protection from nausea and vomiting in cisplatin-treated patients: high-dose metoclopramide combined with methylprednisolone versus metoclopramide combined with dexamethasone and diphenhydramine: a study of the Italian Oncology Group for Clinical Research.
  Journal of Clinical Oncology, 1989
• Dose ranging phase I study of the serotonin antagonist GR38032F for prevention of cisplatin-induced nausea and vomiting.
  Journal of Clinical Oncology, 1989
• GR 38032F (GR-C507/75): a novel compound effective in the prevention of acute cisplatin-induced emesis.
  Journal of Clinical Oncology, 1989
• GR38032F, a 5HT3 receptor antagonist, in the prophylaxis of acute cisplatin-induced nausea and vomiting
  Cancer Chemotherapy and Pharmacology, 1989
• 5‐HT₃ receptor antagonists injected into the area postrema inhibit cisplatin‐induced emesis in the ferret
  British Journal of Pharmacology, 1989
• Phase II Trials of the Serotonin Antagonist GR38032F for the Control of Vomiting Caused by Cisplatin
  JNCI Journal of the National Cancer Institute, 1989
• The efficacy of GR38032F, an Antagonist of 5-hydroxytryptamine-3 (5-HT3) in the prophylaxis of cisplatin (CDDP)-induced nausea and vomiting
  European Journal of Cancer and Clinical Oncology, 1988
• Dose-ranging evaluation of the serotonin antagonist GR-C507/75 (GR38032F) when used as an antiemetic in patients receiving anticancer chemotherapy.
  Journal of Clinical Oncology, 1988
• Antiemetic control and prevention of side effects of anti-cancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide plus dexamethasone. A double-blind, randomized trial
  Cancer, 1987